A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Gilead Sciences
St. Jude Children's Research Hospital
Allogene Therapeutics
Genmab
Allogene Therapeutics
Allogene Therapeutics
Lyell Immunopharma, Inc.
Medical University of Vienna
Novartis
Regeneron Pharmaceuticals
National Cancer Institute, Egypt